I-270 NORTH
Ballwin patients reach our clinic in about twenty-seven minutes via I-270 north. Here we confirm the diagnosis, place PRP or another orthobiologic under imaging, and pair it with loading. Two studies of the same treatment reach opposite conclusions. That is not a reason to dismiss it. It is not a reason to believe the flattering one either.
Getting here from Ballwin
I-270 north to Natural Bridge Road — around twenty-seven minutes, near the outer edge of our ring. Parking at the door.
Why the trials disagree
The research on orthobiologics truly conflicts, and most of the conflict can be explained. It is not a mystery. Studies differ in platelet dose by an order of magnitude. They differ in whether white cells are included, and in whether the injection was image-guided. They differ in whether any loading program ran alongside.
Pool all of those into one meta-analysis and report a null result, and you learn one thing. A mixed set of treatments averages out to nothing. It does not tell you that a well-made, well-placed injection with a rehab program does nothing.
Why the trials disagree sets that out in detail. It is the most useful page on this site for anyone deciding whether to spend money here.
Dose is the variable nobody discloses
Results track platelet dose in the studies that report it. Many clinics do not know, or will not say, what dose their system produces.
It is a fair question to ask anywhere you are thinking about treatment. What PRP actually is covers what varies between systems, and why two things both called PRP are not the same product.
What we publish and what we do not
We do not publish success rates from our own uncontrolled experience, because they would tell you nothing and would look impressive.
What we will give you is the evidence for your specific problem, and an honest estimate based on your own findings.
What we want asked of us
Who does the injection? Is it image-guided? What preparation and platelet dose? What happens if it does not work? Those four questions separate most of this field.
We answer them in writing before treatment, not after. Any clinic that will not is telling you something.
Cost is not evidence
Price varies hugely in this space. It tracks marketing, not preparation quality or outcome. An expensive product is not a better one.
Paying for treatment sets out what is and is not billable before anything is scheduled.
What a null result should change
Where the evidence truly does not support a treatment for a problem, we say so and do not offer it. That list is shorter than the marketing implies, and longer than fans admit.
A practice that can name the problems where it would say no is giving you the most honest signal it can.
Placebo, and taking it seriously
Injection procedures carry a strong placebo effect, which is why uncontrolled case series look impressive. Any clinic quoting success rates from its own uncontrolled experience is telling you very little.
The counterweight is objective measurement — range, strength, function — recorded before and after, instead of a satisfaction score.
What we do with all of that
Confirm the diagnosis. Choose the preparation by tissue. Place it under imaging, and pair it with loading. Then measure. If the measurements do not move, the plan changes instead of repeating.
What is injected is autologous — drawn from you, concentrated, and returned in the same visit. What PRP actually is covers the preparation. PRP versus stem cells covers the products sold at seminars, which are a different thing and not one we offer.
The appointment itself
A first visit takes about an hour. It covers your history, an exam under load, and a reading of the imaging you already have against what actually brings on the pain. What to expect sets out the visit itself. The risks covers what can go wrong, which is a short list but not an empty one.
The ceiling nobody measures
Any honest account of who responds has to include the state of the person, not only the preparation used. The metabolic side covers the markers that predict it.
The subgroup problem, and why averages mislead here
A trial reports an average. Sometimes the group enrolled is a mix — early and advanced disease, tendon and joint, active and sedentary. Then a real benefit limited to one subgroup gets diluted by everyone it was never going to help. The average comes back near zero.
That is not a theoretical criticism. Several of the negative orthobiologic trials enrolled broadly and analyzed everyone as one group. The subgroup analyses that come later are treated as unreliable, precisely because they were not planned in advance. Both positions can be defended, which is why the research stays unsettled longer than either side would like.
What this means for you is that neither a positive nor a negative headline transfers cleanly to one patient. What transfers is a specific question. Does your case look like the group that appeared to benefit? And does anything about you — the stage, the tissue, the metabolic picture — argue against it? That is the conversation the appointment is for. It is a more honest use of the evidence than quoting a summary number in either direction.
What Ballwin patients ask
I read that PRP does not work. Is that true?
For some problems and some preparations, the evidence is truly weak. For others it is reasonable. Lumping them together is the error: the explanation.
How do I judge a clinic?
Ask who does it, whether it is image-guided, what preparation and dose, and what happens if it fails. Plain answers to those four separate most of the field.
Do you ever say no?
Regularly. The exclusions are set out before you drive, not after.
How far is it from Ballwin?
About twenty-seven minutes north on I-270, near the outer edge of the area we serve.
Related reading
12174 Natural Bridge Rd, Suite 303
St. Louis, MO 63044